Wexford Capital’s Emergent Biosolutions EBS Stock Holding History

Wexford Capital’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-288	Closed	-$23K	–	209
2020 Q2	$23K	Buy	+288	New	+$21.5K	0.01%	168

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

SCM

Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

Wexford Capital's EBS Position: Q3 2020 in Review

Wexford Capital sold out of Emergent Biosolutions (EBS) in Q3 2020, closing a stake of 288 shares — an estimated $23K sold.

Wexford Capital first reported a position in EBS in Q2 2020 and held it in 1 quarter. The position peaked at $23K in Q2 2020. 358 funds tracked by Wall St. Rank hold EBS as of Q3 2020.

Wexford Capital reported no remaining Emergent Biosolutions position as of Q3 2020 after selling out during the quarter.
Wexford Capital sold 288 Emergent Biosolutions shares in Q3 2020, an estimated $23K.
Wexford Capital first reported a position in Emergent Biosolutions in Q2 2020 and held it in 1 quarter.
Wexford Capital's Emergent Biosolutions position peaked at $23K in Q2 2020.
358 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q3 2020.

Based on Wexford Capital's 13F filing for Q3 2020, filed 16 Nov 2020.